Nothing Special   »   [go: up one dir, main page]

PT1390042E - Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal - Google Patents

Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal Download PDF

Info

Publication number
PT1390042E
PT1390042E PT02738961T PT02738961T PT1390042E PT 1390042 E PT1390042 E PT 1390042E PT 02738961 T PT02738961 T PT 02738961T PT 02738961 T PT02738961 T PT 02738961T PT 1390042 E PT1390042 E PT 1390042E
Authority
PT
Portugal
Prior art keywords
delivery system
drug delivery
hormonal contraception
tetrahydroxylated estrogen
tetrahydroxylated
Prior art date
Application number
PT02738961T
Other languages
English (en)
Inventor
Herman Jan Tijmen Coelingh Bennink
Christian Franz Holinka
Evert Johannes Bunschoten
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01201945A external-priority patent/EP1293210B1/en
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Publication of PT1390042E publication Critical patent/PT1390042E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT02738961T 2001-05-23 2002-05-23 Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal PT1390042E (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01201945A EP1293210B1 (en) 2001-05-23 2001-05-23 Means and method for hormonal contraception
EP01201946 2001-05-23
EP01201947 2001-05-23
EP01204377 2001-11-15
EP02075695 2002-02-21

Publications (1)

Publication Number Publication Date
PT1390042E true PT1390042E (pt) 2008-03-10

Family

ID=27513107

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02738961T PT1390042E (pt) 2001-05-23 2002-05-23 Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal

Country Status (12)

Country Link
US (1) US7732430B2 (pt)
EP (1) EP1390042B1 (pt)
CA (1) CA2448278C (pt)
CY (2) CY1108093T1 (pt)
DE (1) DE60223795T2 (pt)
DK (1) DK1390042T3 (pt)
ES (1) ES2296943T3 (pt)
FR (1) FR21C1033I2 (pt)
LU (1) LUC00213I2 (pt)
NL (1) NL301115I2 (pt)
PT (1) PT1390042E (pt)
WO (1) WO2002094279A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2298570T3 (es) 2002-10-23 2008-05-16 Pantarhei Bioscience B.V. Composiciones farmaceuticas que comprenden derivados de estetrol para el uso en la terapia del cancer.
CA2505190C (en) 2002-11-08 2012-07-10 Pantarhei Bioscience B.V. Synthesis of estetrol via estrone derived steroids
SG195121A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
HUE029252T2 (en) 2011-06-01 2017-02-28 Estetra Sprl Process for the preparation of intermediates of estetrol
EP2734193B1 (en) 2011-07-19 2015-05-20 Pantarhei Bioscience B.V. Tablet containing dehydroepiandrosterone (dhea)
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
HUE033590T2 (hu) * 2011-08-11 2017-12-28 Estetra Sprl Esztetrol alkalmazása sürgõsségi fogamzásgátlóként
WO2013034780A2 (en) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
ES2624667T3 (es) 2013-09-18 2017-07-17 Crystal Pharma, S.A.U. Procedimiento para la preparación de estetrol
HUE035848T2 (en) 2013-12-12 2018-05-28 Donesta Bioscience B V Solid dispensing unit containing an estetrol compound in the mouth
JP6866561B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロールを含有する口腔内崩壊錠
SI3310333T1 (sl) 2015-06-18 2020-08-31 Estetra Sprl Orodisperzibilna enota odmerka, ki vsebuje komponento estetrola
PE20180398A1 (es) 2015-06-18 2018-02-28 Mithra Pharmaceuticals S A Unidad de dosificacion orodispersable que contiene un componente estetrol
US10888518B2 (en) 2015-06-18 2021-01-12 Estetra Sprl Orodispersible tablet containing estetrol
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
AU2019219070B2 (en) * 2018-02-07 2024-12-19 Estetra Srl Contraceptive composition with reduced cardiovascular effects
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
WO2023152682A1 (en) 2022-02-10 2023-08-17 Estetra Srl Contraceptive methods with scheduled bleeding effects

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2426779A1 (de) 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336434A1 (de) 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336433A1 (de) 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (ja) 1990-07-26 1992-08-24 Sumitomo Chem Co Ltd スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤
US5063507A (en) 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5468736A (en) 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (nl) 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) * 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (en) 1994-08-04 1996-02-15 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
WO1998058657A1 (en) 1997-06-20 1998-12-30 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
AU4543200A (en) 1999-04-16 2000-11-02 Dittgen, Michael Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones
WO2000073416A1 (en) 1999-05-28 2000-12-07 University Of Cincinnati Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
DE60129550T2 (de) 2000-05-12 2008-04-10 The Government Of The United States Of America, As Represented By The Department Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
DK1446128T3 (da) * 2001-11-15 2007-04-02 Pantarhei Bioscience Bv Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling

Also Published As

Publication number Publication date
US20040198710A1 (en) 2004-10-07
CA2448278A1 (en) 2002-11-28
WO2002094279A1 (en) 2002-11-28
EP1390042A1 (en) 2004-02-25
NL301115I1 (pt) 2021-07-14
LUC00213I1 (pt) 2021-07-08
DE60223795D1 (de) 2008-01-10
CA2448278C (en) 2010-06-08
FR21C1033I2 (fr) 2022-04-22
LUC00213I2 (pt) 2021-10-29
FR21C1033I1 (fr) 2021-10-15
EP1390042B1 (en) 2007-11-28
CY1108093T1 (el) 2014-02-12
ES2296943T3 (es) 2008-05-01
CY2021020I1 (el) 2021-12-31
CY2021020I2 (el) 2021-12-31
DK1390042T3 (da) 2008-03-31
DE60223795T2 (de) 2008-11-27
US7732430B2 (en) 2010-06-08
NL301115I2 (nl) 2021-10-25

Similar Documents

Publication Publication Date Title
CY2021020I2 (el) Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη
PT1280520E (pt) Pós à base de fosfolípidos para administração de fármacos
IL155272A0 (en) Systems for optimized drug delivery
HK1072177A1 (en) Drug delivery device
AU6938600A (en) Cervical agent delivery system
AU2001264887A1 (en) Drug delivery device
AU7333601A (en) Drug delivery management system
HUP0401438A3 (en) Drug delivery system
PL355970A1 (en) Ophthalmic drug delivery device
AU2002246500A1 (en) Thermal vaporizing device for drug delivery
AU2001283359A1 (en) Drug release (delivery system)
HUP0300882A3 (en) New self emulsifying drug delivery system
GB0102171D0 (en) A drug delivery service
GB0008494D0 (en) Microprojectile delivery system
AU2513800A (en) Buccal drug delivery system for use in male contraception
GB2355252B (en) Improvements in drug delivery devices
IL151909A0 (en) Peptide conjugates for drug delivery
IL151380A0 (en) New self emulsifying drug delivery system
HK1077523A1 (en) Proliposomal drug delivery system
IL137559A0 (en) Transdermal drug delivery system
IL139177A0 (en) Sustained release drug delivery system
GB0029843D0 (en) Drug delivery system
AU2002311676A1 (en) Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
AU2002311675A1 (en) Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
AU5654701A (en) Drug delivery mask